lystn

In this CCO Nephrology podcast episode, hear from cardiologist Erin D. Michos, MD, MHS, FACC, FAHA, FASE, FASPC, and nephrologist Mark J. Sarnak, MD, MS, as they discuss new and emerging therapies designed to target residual inflammatory risk associated with ASCVD and CKD.   

 Episode outline:   

• Colchicine: inhibition of NLRP3 inflammasome assembly/activation
• Canakinumab (anti–IL-1β monoclonal antibody)
• Ziltivekimab (anti–IL-6 monoclonal antibody)
• Other emerging targets/therapies 

To learn more about targeting residual risk associated with systemic inflammation, find more educational activities and resources with the links below:   

• CME-certified text module with animated pathophysiology video and faculty voice audio clips 
• ClinicalThought commentaries 
• Podcast episode 1, discussing residual risk associated with systemic inflammation and the role of cardiologists and nephrologists in mitigating risk in ASCVD and CKD 
• Podcast episode 2, discussing novel therapeutic approaches to address residual inflammatory risks in patients with ASCVD and CKD